Show simple item record

dc.contributor.authorPlummer, R
dc.contributor.authorSanborn, R
dc.contributor.authorde Vries, E
dc.contributor.authorLorusso, P
dc.contributor.authorArkenau, H
dc.contributor.authorUboha, N
dc.contributor.authorWydmanski, J
dc.contributor.authorFidler, M
dc.contributor.authorBoni, V
dc.contributor.authorGarcia-Corbacho, J
dc.contributor.authorHumphrey, R
dc.contributor.authorWill, M
dc.contributor.authorAutio, K
dc.contributor.authorEl-Khoueiry, A
dc.contributor.authorvan Oordt, C
dc.contributor.authorThistlethwaite, Fiona C
dc.date.accessioned2019-04-29T09:49:01Z
dc.date.available2019-04-29T09:49:01Z
dc.date.issued2018en
dc.identifier.citationPlummer R, Sanborn RE, de Vries EGE, Lorusso P, Arkenau HT, Uboha N, et al. 436P Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors. Ann Oncol. 2018;29(suppl_8):143.en
dc.identifier.doi10.1093/annonc/mdy279.423en
dc.identifier.urihttp://hdl.handle.net/10541/621802
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy279.423en
dc.titlePreliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumorsen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentNorthern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyneen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record